Giant Pfizer to Acquire Tiny Angiosyn
By Business Review Editor
Pharma Deals Review: Vol 2005 Issue 57 (Table of Contents)
Published: 5 Mar-2005
DOI: 10.3833/pdr.v2005.i57.716 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Pharmaceutical giant Pfizer acquires Angiosyn for up to US$527 M, which is focused on the development of biologics for controlling angiogenesis particularly for the treatment of ophthalmic diseases such as macular degeneration and diabetic retinopathy...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS